Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARACK D trial
2012-002672-13Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of spironolactone in chronic kidney disease (CKD) (2 arms), sponsored by University of Oxford. Primary endpoint: Composite of death or first cardiovascular event/hospitalization at 3 years. Status: unknown.
02
Drugs
spironolactone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-002672-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002672-13.